tiprankstipranks
Advertisement
Advertisement
Aktis Oncology initiated with a Buy at H.C. Wainwright
PremiumThe FlyAktis Oncology initiated with a Buy at H.C. Wainwright
2M ago
Aktis Oncology’s NECTINIUM-2 Trial: A New Radiopharma Bet in Solid Tumors
Premium
Company Announcements
Aktis Oncology’s NECTINIUM-2 Trial: A New Radiopharma Bet in Solid Tumors
2M ago
Aktis Oncology: Fast-Track Momentum and Pipeline Catalysts Underpin Buy Rating and $34 Price Target
Premium
Ratings
Aktis Oncology: Fast-Track Momentum and Pipeline Catalysts Underpin Buy Rating and $34 Price Target
2M ago
Aktis Oncology: Differentiated Miniprotein Radiopharma Platform Underpins Buy Rating and Multi-Billion Dollar Sales Potential
PremiumRatingsAktis Oncology: Differentiated Miniprotein Radiopharma Platform Underpins Buy Rating and Multi-Billion Dollar Sales Potential
3M ago
Aktis Oncology initiated with a Buy at TD Cowen
Premium
The Fly
Aktis Oncology initiated with a Buy at TD Cowen
3M ago
Aktis Oncology initiated with an Overweight at JPMorgan
Premium
The Fly
Aktis Oncology initiated with an Overweight at JPMorgan
3M ago
Akoustis Technologies Reports Improved Revenue Amid Legal Challenges
PremiumCompany AnnouncementsAkoustis Technologies Reports Improved Revenue Amid Legal Challenges
1y ago
Akoustis Technologies Names Kamran Cheema CEO and Director
Premium
Company Announcements
Akoustis Technologies Names Kamran Cheema CEO and Director
2y ago
AKTS Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
AKTS Earnings this Week: How Will it Perform?
2y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100